MDxHealth SA ADR

MDxHealth SA is a commercial-stage precision diagnostics company that provides urologic solutions in the United States, Europe, and internationally. Its testing solutions include Confirm mdx, a prostate cancer tissue test that validates an epigenetic test to guide detection of occult prostate cancer in previously biopsied negative tissue; ExoD, a non-invasive urine test to assess the risk of clinically significant prostate cancer; and Resolve mdx for urinary tract infection, which identifies personalized effective antibiotic options. The company also offers a genomic prostate score that provides personalized genomic insights to physicians and patients. It sells products through a urology sales force of direct sales representatives, strategic account managers, and regional sales managers, and has a collaboration for the initiation of Genomic Prostate Score (GPS) testing. Formerly known as OncoMethylome Sciences SA, it changed its name to MDxHealth SA in October 2010, was incorporated in 2003, and is headquartered in Herstal, Belgium.